• Neelima S. Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa
  • Naresh Babu T. Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa
  • Pradeep Kumar M. Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa




Inflammatory bowel disease, Shilajit, Indomethacin, Subcutaneous


Objective: Inflammatory bowel disease (IBD) is a chronic condition of the intestine with unknown etiology involving multiple immunes, genetic and environmental factors. Oxidative stress is believed to be a key factor in the pathogenesis and perpetuation of the mucosal damage in IBD. The present study is to elucidate the effects of shilajit extract on the extent and severity of enterocolitis induced by subcutaneous administration of Indomethacin (7.5 mg/kg b. w) in Wistar rats.

Methods: Study comprised of 6 groups (n=6), normal vehicle control, indomethacin-induced (7.5 mg/kg, 2days), shilajit alone 50 mg/kg b. w, shilajit treated groups (25 and 50 mg/kg, p. o) and sulfasalazine treated (100 mg/kg, p. o) groups. Drug treatment continued for 11 d and on 12th d scarification was done. The colonic mucosal injury was assessed by macroscopic scoring, biochemical (LDH, MPO, GSH and LPO) tests were performed.

Results: Pretreatment with shilajit showed a decrease in macroscopic scores, LDH, MPO, LPO and elevation levels of GSH as compared to the indomethacin-treated group.

Conclusion: The present study suggests that the protective effect of shilajit in indomethacin-induced enterocolitis might be attributed to its scavenging effect on oxygen-derived free radicals and may be beneficial in patients with inflammatory bowel disease.


Download data is not yet available.


Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.

Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007;8:171-8.

Head KA, Jurenka JS. Inflammatory bowel disease part i: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003;8:247-83.

Hanan HH, Azza EM. Ameliorative effect of pyrrolidine dithiocarbamate on acetic acid induced colitis in rat. Eur J Pharmacol 2007;554:69-77.

Ghosal S, Lal J, Singh SK, Goel RK, Jaiswal AK, Bhattacharya SK. The need for formulation of shilajit by its isolated active constituents. Phytother Res 1991b;5:211-6.

Roth MP, Petersen GM, McElree C. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989;97:900–4.

Yamada T, Deitch E, Specian RD, Perry MA, Sartor B, MB Grisham. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-62.

Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.

Jagtap AG, Shirke SS, Phadke AS. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 2004;90:195-204.

Ellman GI. Tissue sulfahydral groups. Arch Biochem Biophys 1957;80:70-7.

Gwlvan G, Saltman P. Different cellular targets of Cu and Fe Catalysed Oxidation observed using a Cu compatible thiobarbiturate acid assay. Biochemica Biophysica Acta 1990;1035:356-60.



How to Cite

S., N., N. Babu T., and P. K. M. “EFFECT OF SHILAJIT ON EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE IN RATS”. International Journal of Current Pharmaceutical Research, vol. 9, no. 4, July 2017, pp. 35-37, doi:10.22159/ijcpr.2017v9i4.20756.



Original Article(s)